Ulti_1170x120_5-11-20

PBMs

New research: PBMs save $962 per person annually

New research: PBMs save $962 per person annually

WASHINGTON — Pharmacy benefit managers (PBMs) save consumers and payers an average of $962 per person per year, according to a new analysis by Visante, a $21 increase from 2016. The research also highlights PBMs’ role in reducing medication errors and improving patients’ health through increased adherence rates and specialty pharmacies. “As prescription drug prices

Rx groups unite to fight PBMs

Rx groups unite to fight PBMs

ALEXANDRIA, Va.  – The National Community Pharmacists Association (NCPA) and the Arkansas Pharmacists Association (APA), along with the American Pharmacists Association (APhA) and the National Alliance of State Pharmacy Associations (NASPA), announced today they will file an amicus curiae brief with the Supreme Court of the United States in support of a case that pits

NCPA endorses bill to ban PBM spread pricing tactic

NCPA endorses bill to ban PBM spread pricing tactic

ALEXANDRIA, Va. — The National Community Pharmacists Association is endorsing H.R. 5281, the Drug Price Transparency in Medicaid Act, which would ban the use of spread pricing by pharmacy benefit managers in Medicaid managed care. Currently, PBMs can overbill Medicaid managed care programs, under-reimburse pharmacies for medications dispensed, and retain the difference, which is referred to as

Independent pharmacies suffer from DIR fees; PBM champions for change

Independent pharmacies suffer from DIR fees; PBM champions for change

GAINESVILLE, Ga. – As more independent pharmacies close or file for bankruptcy across the U.S., industry experts are looking for ways to improve, standardize and make transparent DIR fee calculations as a means to boost pharmacy solvency, particularly in urban and small rural towns, which are being hit the hardest by closures. “It is simply not a

Capital Rx working to lower prescription drug costs 

Capital Rx working to lower prescription drug costs 

NEW YORK — Capital Rx, a next generation pharmacy benefits manager, announced on Wednesday the launch of its Clearinghouse Model, the first major innovation in the way prescriptions are priced for over three decades. Through this new pricing framework, Capital Rx brings full visibility to drug unit prices and eliminates arbitrary price variability for patients

NCPA urges PBM reform in major media print ads

NCPA urges PBM reform in major media print ads

ALEXANDRIA, Va. — In print ads Tuesday in the Washington Post and the Wall Street Journal, the National Community Pharmacists Association is urging policymakers to rein in pharmacy benefit managers to help lower drug costs. These ads complement NCPA’s ongoing efforts in its years-long campaign to reform pharmacy direct and indirect remuneration (DIR) fees, a

PBMs support transparency for consumers, health plan sponsors, policymakers

PBMs support transparency for consumers, health plan sponsors, policymakers

WASHINGTON — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s action by the House Energy and Commerce Subcommittee on Health drug pricing transparency legislation: PCMA applauds the Energy and Commerce Subcommittee on Health for advancing legislation promoting real-time benefit tools to give prescribers and patients at the point of prescribing information on

PBMs support increased transparency in prescription drug supply chain

PBMs support increased transparency in prescription drug supply chain

WASHINGTON — As the Energy and Commerce Subcommittee on Health examines ways to bring more transparency to prescription drug prices, the Pharmaceutical Care Management Association (PCMA) is confirming its principles on transparency in the prescription drug supply chain. PCMA commends the Subcommittee’s work to bring more transparency to drug prices. America’s pharmacy benefit managers (PBMs) support greater

Moriarty addresses prescription drug affordability at Roll Call Live

Moriarty addresses prescription drug affordability at Roll Call Live

  WASHINGTON — In the midst of a very important discussion around prescription drug pricing in Washington, D.C., CVS Health sponsored an event earlier this week with CQ Roll Call titled “Empowering Patients as Partners in Health Care” to focus on the issue and the consumer experience in health care. At the event, policymakers and

Transparent pharmacy benefits needed

Transparent pharmacy benefits needed

NEW YORK — Now more than ever, the media landscape is turning an increasingly critical eye towards pharmacy benefit managers — the health care system’s favorite scapegoats. As health care costs continue to rise at staggering rates, these organizations can help their clients save on drug costs. However, it’s a complicated and confusing minefield in

Higher script volumes aid in Q1 gains for CVS

Higher script volumes aid in Q1 gains for CVS

WOONSOCKET, R.I. — CVS Health’s revenue was on the rise as it filled more prescriptions and benefited from a lower effective tax rate, the company said today in reporting its operating results for the three months ended March 31. The drug store chain said its first quarter revenue increased 2.6% to $45.7 billion from $44.5

CVS kept drug price growth almost flat for PBM clients in 2017

CVS kept drug price growth almost flat for PBM clients in 2017

WOONSOCKET, R.I. — CVS Health has reported that, in 2017, the company kept drug price growth nearly flat for its pharmacy benefit management (PBM) clients, at a minimal 0.2%, despite manufacturer price inflation near 10%. Overall, the combination of this nearly flat drug price growth, with low drug utilization growth of 1.7%, reduced drug trend

What’s the story with PBMs?

What’s the story with PBMs?

A lobbying event in Washington has triggered salvoes between two combatants: independent community pharmacies and pharmacy benefit managers. The National Community Pharmacists Association is holding its Congressional Pharmacy Fly-In advocacy drive this week, where it will also release “The PBM Story: What They Say, What They Do, and What Can Be Done About It,” offered

Senator: C-THRU bill ‘shines light’ on drug pricing

Senator: C-THRU bill ‘shines light’ on drug pricing

WASHINGTON — Sen. Ron Wyden (D., Ore.) has introduced the Creating Transparency to Have Drug Rebates Unlocked Act (C-THRU), aimed at bringing more visibility into prescription drug pricing by pharmacy benefit managers. The C-THRU legislation, initiated Wednesday in the Senate Finance Committee, would require PBMs serving Medicare Part D plans to disclose the aggregate rebates